Fabry disease and the skin: data from FOS, the Fabry outcome survey

被引:93
|
作者
Orteu, C. H. [1 ]
Jansen, T.
Lidove, O.
Jaussaud, R.
Hughes, D. A.
Pintos-Morell, G.
Ramaswami, U.
Parini, R.
Sunder-Plassman, G.
Beck, M.
Mehta, A. B.
机构
[1] Royal Free Hosp, Dept Dermatol, London NW3 2QG, England
[2] Royal Free Hosp, Dept Haematol, London NW3 2QG, England
[3] Ruhr Univ Bochum, Dept Dermatol, Bochum, Germany
[4] Hop Xavier Bichat, Dept Internal Med, Paris, France
[5] Hop Robert Debre, Dept Internal Med & Infect Dis, Reims, France
[6] Univ Hosp Germans Trias & Pujol, Dept Paediat, Badalona, Spain
[7] Addenbrookes Hosp, Dept Paediat, Cambridge, England
[8] Univ Milan, Dept Paediat, Monza, Italy
[9] Med Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Vienna, Austria
[10] Johannes Gutenberg Univ Mainz, Mainz, Germany
关键词
angiokeratoma; Fabry disease; hyperhidrosis; hypohidrosis; lymphoedema; telangiectasia;
D O I
10.1111/j.1365-2133.2007.08002.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Fabry disease (also known as Anderson-Fabry disease) is a rare, X-linked lysosomal storage disorder that is characterized by accumulation of globotriaosylceramide throughout a range of tissues in the body. Objectives To ascertain the prevalence and nature of cutaneous manifestations in patients with Fabry disease and to relate these to the severity of systemic manifestations of the disease. Methods We have documented the dermatological features of this disease with reference to data from 714 patients (345 males, 369 females) registered on the Fabry Outcome Survey (FOS), a multicentre European database. Results We confirm that the commonest disease manifestation is angiokeratoma. Overall, 78% of males and 50% of females had one or more dermatological abnormality, the commonest being angiokeratoma (66% males, 36% females), hypohidrosis (53% males, 28% females), telangiectasia (23% males, 9% females) and lymphoedema (16% males, 6% females). We demonstrate for the first time that the presence of cutaneous vascular lesions correlates with the severity of the systemic manifestations of the disease (pain, renal failure, cardiac disease, premature cerebrovascular disease) as assessed by a severity scoring system. Although the condition is X linked, there is a surprisingly high prevalence of abnormalities in females. Conclusions The FOS database is a useful epidemiological tool in establishing the variety and relevance of cutaneous manifestations in Fabry disease. The present study confirms that the presence of dermatological manifestations appears to be a marker of greater severity of systemic disease, which emphasizes the importance of the dermatological assessment of these patients.
引用
下载
收藏
页码:331 / 337
页数:7
相关论文
共 50 条
  • [21] Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey
    Sodi, Andrea
    Ioannidis, Alexander S.
    Mehta, Atul
    Davey, Clare
    Beck, Michael
    Pitz, Susanne
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2007, 91 (02) : 210 - 214
  • [22] Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey
    Hajioff, D.
    Hegemannn, S.
    Conti, G.
    Beck, M.
    Sunder-Plassmann, G.
    Widmer, U.
    Mehta, A.
    Keilmann, A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (09) : 663 - 667
  • [23] Clinical manifestations of Fabry disease in children: Data from the Fabry outcome survey
    Ramaswami, U
    Whybra, C
    Parini, R
    Pintos-Morell, G
    Mehta, A
    Sunder-Plassmann, G
    Widmer, U
    Beck, M
    ACTA PAEDIATRICA, 2006, 95 (01) : 86 - 92
  • [24] Fabry Outcome Survey (FOS): Highlights from a 20-year patient registry of Fabry disease
    Beck, Michael
    Ramaswami, Uma
    Hughes, Derralynn
    Kampmann, Christoph
    Nicholls, Kathy
    Niu, Dau-Ming
    Reisin, Ricardo
    Pintos-Morell, Guillem
    West, Michael
    Schenk, Joern
    Anagnostopoulou, Christina
    Botha, Jaco
    Jazukeviciene, Dalia
    Giugliani, Roberto
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S19 - S19
  • [25] EARLY ONSET AND EVOLVING CLINICAL PRESENTATION OF FABRY DISEASE IN CHILDREN AND YOUNG ADULTS: DATA FROM FOS - THE FABRY OUTCOME SURVEY
    Pintos Morell, G.
    Ramaswami, U.
    Parini, R.
    Whybra, C.
    Beck, M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 164 - 164
  • [26] Characterisation of ischaemic stroke in Fabry disease: data from the international Fabry outcome survey
    Ginsberg, L.
    Manara, R.
    Reinke, J.
    Jardim, L.
    Mehta, A.
    Burlina, A. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 21 - 22
  • [27] Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS)
    Barba-Romero, M. -A.
    Rivera-Gallego, A.
    Pintos-Morell, G.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (08) : 903 - 910
  • [28] Positive European experience with agalsidase alfa in Fabry disease: update from FOS - the Fabry Outcome Survey.
    Mehta, A
    Beck, M
    Dehout, F
    de Lorenzo, AG
    Hauge, G
    Jaeger, P
    Kampmann, C
    Linhart, A
    Ricci, R
    Sunder-Plassman, G
    Widmer, U
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 453 - 453
  • [29] POSITIVE RESULTS FROM 3 YEARS OF ENZYME REPLACEMENT THERAPY WITH AGALSIDASE ALFA IN FABRY DISEASE: DATA FROM FOS - THE FABRY OUTCOME SURVEY
    Beck, M.
    Sunder-Plassmann, G.
    Mehta, A.
    Widmer, U.
    Linhart, A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 : 164 - 164
  • [30] Response of women with Fabry disease to enzyme replacement therapy: Comparison with men, using data from FOS-the Fabry Outcome Survey
    Hughes, Derralynn A.
    Barba Romero, Miguel-Angel
    Hollak, Carla E. M.
    Giugliani, Roberto
    Deegan, Patrick B.
    MOLECULAR GENETICS AND METABOLISM, 2011, 103 (03) : 207 - 214